Background: Tumor budding is a readily detectable histopathologic feature that has been recognized as an adverse prognostic factor in several human cancers.
C utaneous squamous cell carcinoma (cSCC) is the second most common malignancy in humans, with an incidence of 16 per 100,000 people in Europe. 1 Approximately 5% of cSCCs metastasize, usually to regional lymph nodes. 2 Within the current tumor node metastasis (TNM) classification of nonmelanoma skin cancers by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer, the primary tumor is characterized by a combination of horizontal size and ''high-risk factors'' (HRFs). 1 According to this staging system, T1 tumors are #20 mm in greatest dimension with \2 HRFs, T2 tumors are [2 cm in greatest dimension with or without 1 additional HRF, or any size with $2 HRFs, T3 tumors are with invasion of maxilla, mandible, orbit, or temporal bone, and T4 are tumors with invasion of skeleton (axial or appendicular) or perineural invasion of skull base. Several characteristics, such as primary site on ear or hair-bearing lip, poor differentiation, thickness, anatomic level, presence of perineural invasion, and presence of lymphovascular invasion have been included as HRFs. 1 Moreover, other characteristics, such as inflammatory response, association with actinic keratosis, with human papillomavirus, with Bowen disease, and some kind of histologic subtypes (eg, acantholytic, basaloid, small cell, signet ring, desmoplastic or spindle cell histologic subtypes, and follicular cSCC) have also been suggested as prognostic factors. [2] [3] [4] [5] [6] In the United States, Brigham and Women's Hospital (BWH) staging is becoming the preferred staging system, because it offers improved distinctiveness, homogeneity, and monotonicity over AJCC and International Union Against Cancer staging, but population-based validation is needed. BWH's staging system is as follows: T1 = 0 HRFs, T2a = 1 HRF, T2b = 2 to 3 HRFs, and T3 = $4 HRFs; HRFs include a tumor diameter $2 cm, poorly differentiated histology, perineural invasion $0.1 mm, and tumor invasion beyond fat, excluding bone invasion, which automatically upgrades tumors to stage T3. 7 Wang et al 8 proposed that cancer cells located in the invasive tumor front are more aggressive in terms of metastatic potential. Tumor budding is defined as the presence of either isolated single cells or small cell clusters (#4) scattered in the stroma ahead of the invasive tumor front. 9 Budding represents 2 malignant features: cellular discohesion and active invasion. Their presence has been considered a characteristic of aggressive cancer. Tumor budding has previously been found as a prognostic marker for colorectal cancer patients, 9 ampullary adenocarcinoma, 10 lung carcinoma, 11 laryngeal cancers, 12 and tongue SCC. 8 With the goal of studying the possible association of tumor budding and clinicopathologic features and establish their potential prognostic value in cSCC, a retrospective study was performed.
METHODS

Patients and procedures
The 
Histopathologic evaluation
Two evaluators (GM and BV) independently analyzed each sample and registered the following histopathologic features using hematoxylineeosin (H&E)-stained slides: maximum diameter, tumor thickness, anatomic level (Clark level), histopathologic degree of differentiation, presence of desmoplasia, perineural or perivascular invasion, and the presence and number of tumor budding (defined as the presence of either isolated single cells or small cell clusters, #4 cells, scattered in the stroma ahead of the invasive tumor front). The median number of slides per case available for analysis was 4 (range, 1-5 slides). Tumor specimens were initially scanned to select the areas with the highest density of budding. Tumor budding in the selected areas was then counted using the 340 objective lens, and the highest count per slide was used as the number of budding. The cases were deemed either positive ($1 buds present) or negative (no buds present) for tumor budding. The intensity of tumor budding (budding index) was classified as low (\5 buds) or high ($5 buds) based on the study by Wang et al. 8 There was total agreement among the 2 pathologists about the presence or absence of tumor budding. In We confirmed most risk factors and identified tumor buds as a predictor for lymph node metastasis. The importance of tumor buds as criteria of high-risk cutaneous squamous cell carcinoma needs confirmation in prospective studies.
addition, excellent agreement was obtained for the budding index between both observers (k = 0.816), based on a hierarchical kappa test. Discrepant cases were reevaluated and the disagreement resolved.
Pathologic tumor staging based on the seventh edition of AJCC classification was also registered. 1 Outcome data were based on 1 tumor per patient.
Statistical analysis
Baseline demographic and clinical characteristics of the patients and pathological data were summarized with standard descriptive statistics. The primary endpoints were time to lymph node metastasis and time to the death, defined as the time from date of diagnosis of the primary tumor to date of diagnosis of metastasis or death, respectively. To identify predictors for fatal outcomes, we selected several features previously known to be HRFs: tumor size (#20 mm or [20 mm), tumor thickness (#2.0 mm, 2.1-6 mm, or [6 mm), Clark level (\4 or $4), desmoplastic growth, site of primary tumor, number of previous cSCCs, presence of immunosuppression, and budding index.
Crude and adjusted hazard ratios (HRs) were calculated with 95% confidence intervals (CIs) by using of the Cox proportional hazards model. Probabilities of nodal metastasis-free survival and overall survival were estimated by KaplaneMeier. The simultaneous prognostic effect of various factors was determined in a multivariate analysis by using of the Cox proportional hazard regression model. The kappa index was used to identify the correlation between the presence of tumor buds and the other variables. We did not find any tumor with thickness \2 mm, and then we dichotomized tumor thickness (#6 mm or [6 mm).
All reported P values are 2-sided, and P \.05 was considered statistically significant.
RESULTS
Ninety-eight white patients were enrolled in the study (Table I ). The median follow-up was 4.28 years (range, 0.70-12 years), with total patient-years of 432.5. Tumor budding was observed in 45 cases (46%) with a mean tumor bud count of 5.9 6 3.9 (range, 1-20 buds). High-intensity budding ($5 tumor buds) was observed in 20 tumors. As shown in Fig 1, tumor buds can be readily identified based on standard H&E staining.
No relevant associations between the candidate predictors were noted except a moderate correlation between tumor thickness and horizontal size (Spearman rank correlation coefficient = 0.668; P \.001) based on the original scales (mm).
Twelve patients from the McSCC group suffered local recurrence before the regional lymph node metastasis. In 5 patients, nodal metastasis occurred within the first year after resection. Two nodal metastases were detected immediately after the cSCC surgery.
On univariate analysis, increased tumor thickness, anatomic level, increased tumor size, poor tumor differentiation, desmoplastic growth, pathologic staging, perineural invasion, lymphovascular invasion, and the presence of tumor buds were significantly associated with nodal metastasis (Table I) .
Tumor buds were associated with tumor thickness, anatomic level, tumor horizontal size, tumor differentiation, desmoplastic growth, pathologic staging, and perineural invasion (Table II) .
On the univariate model, the presence of buds has much effect on the risk of recurrence and death caused by the tumor. While 50% of patients without buds were still alive 5.23 years after treatment (95% CI, 4.48-8.56), 50% of patients with buds had died before 2.95 (95% CI, 2.07-4.78) years and relapsed or died before 1.03 years (95% CI, 0.62-1.48), with a crude HR of 8.92 (95% CI, 4.39-18.1). This effect is slightly modulated but it was still important when it was adjusted by different potential confounders (Table III) . The smallest HR was observed in model 2, with a HR of 6.85 (95% CI, 3.03-15.4). In addition, the presence of tumor buds was associated with a lower overall survival with a HR of 2.03 (95% CI, 1.26-3.28). Again, this HR is modulated when it was adjusted by possible confounders: the smallest HR was observed in model 3, just adjusting by tumor thickness (HR = 1.72 [95% CI, 1.05-2.83]). However, as shown in the last column of Table III , in all models, tumor buds lose their prognostic significance once nodal metastasis occursdthat is, once a tumor metastasizes, it has the same risk of death regardless of their tumor buds.
As shown in Fig 2, top left, a striking difference in nodal metastasis-free survival rates was observed between the budding and no budding groups. At the third year, the difference yields 65% (20% vs 85% for the budding and no budding groups, respectively [P\.001]). Higher differences in nodal metastasis-free survival were even observed when low and high tumor budding were compared (Fig 2, bottom left ; P \.001).
Regarding overall survival, it was significantly lower in the group with tumor buds (Fig 2, top  right) . At the third year, a 50% difference in survival was observed (45% vs. 95% for the budding and no budding groups, respectively; P \ .001). These differences were even higher when the low and high tumor budding groups were compared (Fig 2,  bottom right ; P \.001).
DISCUSSION
In this study, we assessed the role of buds as prognostic factor for lymphatic metastases in cSCC. Based on data from previous studies, 6 ,13 we CI, Confidence interval; cSCC, cutaneous squamous cell carcinoma; HR, hazard ratio; McSCC, nodal metastasis from cutaneous squamous cell carcinoma; SD, standard deviation; TNM, tumor node metastasis.
retrospectively analyzed the prognostic factors associated with cSCC including age, TNM staging, tumor site, tumor thickness, tumor horizontal size, anatomic level, tumor differentiation, desmoplastic growth, tumor site, multiple cSCCs, immunosuppression, perineural invasion, lymphovascular invasion, and tumor budding. Tumor budding, which resides ahead the invasive front, has recently been suggested as a potential index of aggressiveness and poor prognosis for a number of cancer types. [8] [9] [10] [11] [12] 14, 15 An important advantage of tumor buddingebased index as prognostic indicator is the simplicity and reproducible measurement of the budding. It is readily adaptable to routine H&E stainingebased histopathologic examination without the need for additional costly techniques. This feature is important and may have therapeutic implications for patients with SCC. In this study, in accordance with previous reports in other cancers, a good reproducibility for tumor budding evaluation was achieved based on the intra-and interobserver agreement studies (k = 0.880 or 0.818 and 0.717, respectively). 9, 14, 16 However, in a subset of poorly differentiated carcinomas, it may be difficult to identify isolated individual budding tumor cells among the surrounding tissue, which contains inflammatory cells, cancer-associated fibroblasts, and other stromal cells. To highlight budding status in such cases, an additional staining for pan-cytokeratin can be performed. At this moment, it is important note that budding status cannot be assessed in small or shave biopsy specimens that do not include the advancing front of the tumor.
Nothing is known about the prognostic value of tumor budding in patients with cSCC. In this study, we found that overall survival was significantly reduced in patients exhibiting tumor budding compared to patients without tumor budding. In the univariate analysis, tumor budding has the highest HR for metastasis (HR = 8.92 [95% CI, 4.39-18.1]) after the anatomic level (\4 vs $4; HR = 10.6 [95% CI, 2.60-43.5]) and, obviously, the pathologic staging variables (HR = 26.9 [95% CI, 1.03-703.0]). In different multivariate analysis models, patients with buds had 1.7 to 2.5 increased risk of death and 6.3 to 9.5 increased risk of nodal metastasis. This was also observed on studies in other solid tumors (eg, laryngeal and esophageal cancer, colorectal cancer) that also showed strong associations of tumor budding with a poor prognosis. 10, 12, 17, 18 We are well aware that there are several limitations in our report. First, there are potential biases because of the retrospective nature of our study. Second, the study is limited to H&N cSCC. Third, these findings might even be biased, because, in a university hospital, the percentage of poor prognostic tumors might be higher because of referral than in the daily ambulatory practice. We note that in our sample, all the examined tumors are thicker than 2 mm and all of them are from a primary excision. Therefore, the analysis of tumor budding in smaller tumors was not performed and its significance in these cases is uncertain. Surprisingly, neither location on the ear or immunosuppression bore a significantly increased risk of metastasis. In contrast with other studies, immunosuppression has not been associated with poor outcomes. 6, 19, 20 Haisma et al 13 presented similar results about the lack of this association. This may be because immunocompromised patients were compared to immunocompetent patients with a large number of high-risk H&N cSCCs. Another possible explanation is that the number of immunosuppressed cases is too small (12.2%) to obtain significant associations. In several studies, the ear location has high rates of nodal metastasis, 19, 20 but like Brantsch et al 6 we did not find the ear as a risk location for McSCC. Again, the lack of statistical power because of relatively low numbers of patients with this feature may explain these results.
In conclusion, we addressed the independent prognostic relevance of tumor cell budding in patients with cSCC. On the basis of this data, if this is confirmed in prospective studies, we suggest to add tumor buds as criteria of high-risk cSCCs, at least in cSCC of the H&N.
